These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32510188)

  • 1. Is the universal population Hepatitis C virus screening a cost-effective strategy? A systematic review of the economic evidence.
    Ledesma F; Buti M; Domínguez-Hernández R; Casado MA; Esteban R
    Rev Esp Quimioter; 2020 Aug; 33(4):240-248. PubMed ID: 32510188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the cost-effectiveness of hepatitis C screening strategies in France.
    Deuffic-Burban S; Huneau A; Verleene A; Brouard C; Pillonel J; Le Strat Y; Cossais S; Roudot-Thoraval F; Canva V; Mathurin P; Dhumeaux D; Yazdanpanah Y
    J Hepatol; 2018 Oct; 69(4):785-792. PubMed ID: 30227916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population.
    Kim KA; Chung W; Choi HY; Ki M; Jang ES; Jeong SH
    Liver Int; 2019 Jan; 39(1):60-69. PubMed ID: 29998565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is increased hepatitis C virus case-finding combined with current or 8-week to 12-week direct-acting antiviral therapy cost-effective in UK prisons? A prevention benefit analysis.
    Martin NK; Vickerman P; Brew IF; Williamson J; Miners A; Irving WL; Saksena S; Hutchinson SJ; Mandal S; O'Moore E; Hickman M
    Hepatology; 2016 Jun; 63(6):1796-808. PubMed ID: 26864802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era.
    Cortesi PA; Barca R; Giudicatti G; Mossini S; Ciaccio A; Iannazzo S; Micale M; Cesana G; Mantovani LG
    Aliment Pharmacol Ther; 2019 May; 49(9):1126-1133. PubMed ID: 30843268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population.
    Ethgen O; Sanchez Gonzalez Y; Jeanblanc G; Duguet A; Misurski D; Juday T
    J Med Econ; 2017 Feb; 20(2):162-170. PubMed ID: 27590836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Universal Screening for Hepatitis C Virus Infection in the Era of Direct-Acting, Pangenotypic Treatment Regimens.
    Eckman MH; Ward JW; Sherman KE
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):930-939.e9. PubMed ID: 30201597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eradicating hepatitis C: Are novel screening strategies for people who inject drugs cost-effective?
    Manca F; Robinson E; Dillon JF; Boyd KA
    Int J Drug Policy; 2020 Aug; 82():102811. PubMed ID: 32585583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of screening for hepatitis C virus: a systematic review of economic evaluations.
    Coward S; Leggett L; Kaplan GG; Clement F
    BMJ Open; 2016 Sep; 6(9):e011821. PubMed ID: 27601496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling the Impact and Cost-effectiveness of Extended Hepatitis C Virus Screening and Treatment with Direct-acting Antivirals in a Swiss Custodial Setting.
    Girardin F; Hearmon N; Castro E; Negro F; Eddowes L; Gétaz L; Wolff H
    Clin Infect Dis; 2019 Nov; 69(11):1980-1986. PubMed ID: 30715266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of the Hepatitis C virus elimination program in the country of Georgia, 2015 to 2017.
    Tskhomelidze I; Shadaker S; Kuchuloria T; Gvinjilia L; Butsashvili M; Nasrullah M; Gabunia T; Gamkrelidze A; Getia V; Sharvadze L; Tsertsvadze T; Zarqua J; Tsanava S; Handanagic S; Armstrong PA; Averhoff F; Vickerman P; Walker JG
    Liver Int; 2023 Mar; 43(3):558-568. PubMed ID: 36129625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of Universal Hepatitis C Virus Screening of Pregnant Women in the United States.
    Chaillon A; Rand EB; Reau N; Martin NK
    Clin Infect Dis; 2019 Nov; 69(11):1888-1895. PubMed ID: 30689769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review.
    Saab S; Kullar R; Khalil H; Gounder P
    J Clin Gastroenterol; 2021 Mar; 55(3):250-257. PubMed ID: 32324677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
    Chhatwal J; He T; Lopez-Olivo MA
    Pharmacoeconomics; 2016 Jun; 34(6):551-67. PubMed ID: 26748919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of interventions targeting harm reduction and chronic hepatitis C cascade of care in people who inject drugs: The case of France.
    Cousien A; Tran VC; Deuffic-Burban S; Jauffret-Roustide M; Mabileau G; Dhersin JS; Yazdanpanah Y
    J Viral Hepat; 2018 Oct; 25(10):1197-1207. PubMed ID: 29660211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal screening and treatment towards the elimination of chronic hepatitis C in China: an economic evaluation.
    Fang K; Wang HL; Lin Y; Zheng L; Li S; Wu J
    Public Health; 2024 Mar; 228():186-193. PubMed ID: 38387115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The testing of people with any risk factor for hepatitis C in community pharmacies is cost-effective.
    Buchanan R; Cooper K; Grellier L; Khakoo SI; Parkes J
    J Viral Hepat; 2020 Jan; 27(1):36-44. PubMed ID: 31520434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective.
    Kim HL; Kim KA; Choi GH; Jang ES; Ki M; Choi HY; Jeong SH
    Clin Mol Hepatol; 2022 Jan; 28(1):91-104. PubMed ID: 34736311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.